Review



anti ccl2 antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    R&D Systems anti ccl2 antibody
    Anti Ccl2 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ccl2/Canine+CCL2%2FJE%2FMCP-1+Antibody/pm41910735-67-17-19
    Average 90 stars, based on 8 article reviews
    anti ccl2 antibody - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Development and validation of a potency assay matrix for optimized and consistent manufacture of clinical mesenchymal stem/stromal cells.
    Article Snippet: 16hrs before the assay, 300,000MSCs were seeded per well of a 24- well plate (Corning, 3398, 3μm pore size) without the insert in 500μL cRPMI or 500μL MSC-CM was added per well without the insert. .. 1hr before the addition of monocytes 2μg/mL anti-CCL2 (R&D Systems, MAB679) or 75ng/mL recombinant CCL2 (ThermoFisher, 300-04) were added where indicated. ..

    Article Title: Development and validation of a potency assay matrix for optimized and consistent manufacture of clinical mesenchymal stem/stromal cells
    Article Snippet: 16hrs before the assay, 300,000 MSCs were seeded per well of a 24-well plate (Corning, 3398, 3μm pore size) without the insert in 500μL cRPMI or 500μL MSC-CM was added per well without the insert. .. 1hr before the addition of monocytes 2μg/mL anti-CCL2 (R&D Systems, MAB679) or 75ng/mL recombinant CCL2 (ThermoFisher, 300-04) were added where indicated. ..

    Blocking Assay:

    Article Title: Crosstalk of human coronary perivascular adipose-derived stem cells with vascular cells: role of tissue factor.
    Article Snippet: The coronary perivascular adipose tissue (cPVAT) has been associated to the burden of cardiovascular risk factors and to the underlying vessel atherosclerotic plaque severity.. Although the “outside to inside” hypothesis of PVAT-derived-adipokine regulation of vessel function is currently accepted, whether the resident mesenchymal stem cells (ASCs) in PVAT have a regulatory role on the underlying vascular arterial smooth muscle cells (VSMCs) is not known.. Here, we investigated the interactions between resident PVAT-ASCs and VSMCs.

    Binding Assay:

    Article Title: Crosstalk of human coronary perivascular adipose-derived stem cells with vascular cells: role of tissue factor.
    Article Snippet: The coronary perivascular adipose tissue (cPVAT) has been associated to the burden of cardiovascular risk factors and to the underlying vessel atherosclerotic plaque severity.. Although the “outside to inside” hypothesis of PVAT-derived-adipokine regulation of vessel function is currently accepted, whether the resident mesenchymal stem cells (ASCs) in PVAT have a regulatory role on the underlying vascular arterial smooth muscle cells (VSMCs) is not known.. Here, we investigated the interactions between resident PVAT-ASCs and VSMCs.

    Western Blot:

    Article Title: Crosstalk of human coronary perivascular adipose-derived stem cells with vascular cells: role of tissue factor.
    Article Snippet: The coronary perivascular adipose tissue (cPVAT) has been associated to the burden of cardiovascular risk factors and to the underlying vessel atherosclerotic plaque severity.. Although the “outside to inside” hypothesis of PVAT-derived-adipokine regulation of vessel function is currently accepted, whether the resident mesenchymal stem cells (ASCs) in PVAT have a regulatory role on the underlying vascular arterial smooth muscle cells (VSMCs) is not known.. Here, we investigated the interactions between resident PVAT-ASCs and VSMCs.

    Article Title: Integrated analysis of single-cell and bulk RNA-seq data identifies NR4A1-associated macrophages in immunoglobulin A nephropathy.
    Article Snippet: Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerulonephritis worldwide, is characterized by chronic renal inflammation and progressive decline toward end-stage renal disease.. In this study, we integrated single-cell and bulk RNA sequencing approaches to systematically elucidate the role of macrophages in IgAN pathogenesis.. Single-cell transcriptomic analysis identified 171 macrophage-associated differentially expressed genes and revealed two distinct molecular subtypes with divergent immune and metabolic signatures.

    Immunohistochemistry:

    Article Title: Integrated analysis of single-cell and bulk RNA-seq data identifies NR4A1-associated macrophages in immunoglobulin A nephropathy.
    Article Snippet: Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerulonephritis worldwide, is characterized by chronic renal inflammation and progressive decline toward end-stage renal disease.. In this study, we integrated single-cell and bulk RNA sequencing approaches to systematically elucidate the role of macrophages in IgAN pathogenesis.. Single-cell transcriptomic analysis identified 171 macrophage-associated differentially expressed genes and revealed two distinct molecular subtypes with divergent immune and metabolic signatures.

    Transfection:

    Article Title: Epigenomic analyses identify FOXM1 as a key regulator of anti-tumor immune response in esophageal adenocarcinoma
    Article Snippet: .. In a 24-well plate, 400 μL of culture media was collected from YTN5 and YTN16 cells first transfected with FOXM1 siRNA for 24 h, exposure to 20 ng/mL IFNγ (Abcam, #9922) for 24 h, followed by 24-h treatment of (0.5 μg/mL) anti-CCL2 (R&D Systems, #AF-479-SP). .. CD8 + T cells were isolated from the spleens of C57BL/6 mice using the MojoSortTM Mouse CD8 + T Cell Isolation Kit (Biolegend, #480035), followed by 1X Red Blood Cell lysis buffer (eBioscience, #00-4333-57) for 5 min. A 6.5 mm insert with 8.0 μm polycarbonate membranes (COSTAR, #3422) was placed on top of the wells containing culture media.



    Similar Products

    86
    Servicebio Inc ccl2
    Ccl2, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ccl2/2+anti+ccl/pm42320983-61-36-37
    Average 86 stars, based on 1 article reviews
    ccl2 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Signalway Antibody ccl2 mcp 1
    Ccl2 Mcp 1, supplied by Signalway Antibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ccl2/1+anti+ccl2+mcp/pm42249304-157-8-11
    Average 86 stars, based on 1 article reviews
    ccl2 mcp 1 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    94
    Novus Biologicals mcp 1
    Positive area-staining by antibody in intranasally-treated GHK-Cu mice of both sexes for (A) Synaptophysin, (B) GFAP, (C) <t>MCP-1,</t> (D) PSD-95, and (E) TGF-β. ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Mcp 1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ccl2/CCL2%2FMCP1+Antibody+-+BSA+Free/bio_rxiv__64898__2026__04__09__717524-43-24-26
    Average 94 stars, based on 1 article reviews
    mcp 1 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    90
    R&D Systems anti ccl2 antibody
    Positive area-staining by antibody in intranasally-treated GHK-Cu mice of both sexes for (A) Synaptophysin, (B) GFAP, (C) <t>MCP-1,</t> (D) PSD-95, and (E) TGF-β. ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Anti Ccl2 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ccl2/Canine+CCL2%2FJE%2FMCP-1+Antibody/pm41910735-67-17-19
    Average 90 stars, based on 1 article reviews
    anti ccl2 antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    94
    R&D Systems anti ccl2 mouse monoclonal antibody
    Positive area-staining by antibody in intranasally-treated GHK-Cu mice of both sexes for (A) Synaptophysin, (B) GFAP, (C) <t>MCP-1,</t> (D) PSD-95, and (E) TGF-β. ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Anti Ccl2 Mouse Monoclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ccl2/Mouse+CCL2%2FJE%2FMCP-1+Antibody/pm41832208-257-44-49
    Average 94 stars, based on 1 article reviews
    anti ccl2 mouse monoclonal antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    R&D Systems anti ccl2
    Positive area-staining by antibody in intranasally-treated GHK-Cu mice of both sexes for (A) Synaptophysin, (B) GFAP, (C) <t>MCP-1,</t> (D) PSD-95, and (E) TGF-β. ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Anti Ccl2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ccl2/Human+CCL2%2FJE%2FMCP-1+Antibody/pm41798920-102-7-8
    Average 94 stars, based on 1 article reviews
    anti ccl2 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    R&D Systems anti human ccl2 neutralizing antibody
    METH enhances HIV-1 NL4-3 replication in HBVPs independently of Sigma-1R. A - B Impact of METH (25 µM) on HIV-1 replication as measured by p24 antigen release levels in HBVPs infected with HIV-1 NL4-3 ( A ) or JR-CSF ( B ). Data are means ± SEM ( n = 3). C - D Impact of METH (25 µM) on HIV-1 replication as measured by HIV-1 Gag mRNA expression levels in HBVPs infected with HIV-1 NL4-3 ( C ) or JR-CSF ( D ) ( n = 4–5). E Impact of pretreatment with S1RA (10 µM) for 6 h on NL4-3 HIV-1 replication in the presence and absence of METH ( n = 3–4). F Impact of HBVP pretreatment with the CXCR4 chemokine receptor antagonist AMD070 (5 µM) for 1 h on HIV-1 NL4-3 replication in the presence and absence of METH ( n = 4). G The heat map demonstrating the impact of HIV-1 NL4-3 infection and/or METH treatment for 72 h on gene expression profile of 42 ISGs in HBVPs ( n = 6). Genes with high expression levels are represented in shades of red, while those with low expression levels are shown in shades of green. Gene names are shown on the x axis. Red arrows indicate genes that were significantly differentially regulated in the HIV-1 NL4-3 + METH group compared to the control group, as determined by the RT² Profiler PCR Array ( p < 0.05). H - K RT-qPCR analysis of mRNA expression of <t>CCL2</t> ( H ), MX2 ( I ), IFI30 ( J ), and PRKD2 ( K ) in HBVPs infected with HIV-1 NL4-3 and/or treated with METH ( n = 12). L Impact of blocking endogenous CCL2 with anti-human CCL2 neutralizing antibody on p24 release in HIV-1 NL4-3-infected HBVPs, with or without METH, at 72 h post-infection ( n = 6). M Impact of pretreatment with the CXCR4 chemokine receptor antagonist AMD070 (5 µM) for 1 h on CCL2 release in the presence and absence of METH at 72 h post-infection ( n = 6). Data are means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. Abbreviations as in Fig. ; CCL2 - C-C motif chemokine ligand 2
    Anti Human Ccl2 Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ccl2/Human+CCL2%2FJE%2FMCP-1+Antibody/pmc13077830-52-8-14
    Average 93 stars, based on 1 article reviews
    anti human ccl2 neutralizing antibody - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Positive area-staining by antibody in intranasally-treated GHK-Cu mice of both sexes for (A) Synaptophysin, (B) GFAP, (C) MCP-1, (D) PSD-95, and (E) TGF-β. ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Journal: bioRxiv

    Article Title: Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs

    doi: 10.64898/2026.04.09.717524

    Figure Lengend Snippet: Positive area-staining by antibody in intranasally-treated GHK-Cu mice of both sexes for (A) Synaptophysin, (B) GFAP, (C) MCP-1, (D) PSD-95, and (E) TGF-β. ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Article Snippet: Following blocking, sections were incubated overnight at 4°C with primary antibodies against synaptophysin (1:250, Invitrogen MA5-16402), PSD95 (1:250, Abcam ab18258), phospho-SMAD2 (1:50, Invitrogen 44-244G), MCP-1 (1:800, Novus NBP1-07035), p21 (1:200, Abcam ab188224), TGF-β (1:50, Abcam ab215715), and GFAP (1:1500, Invitrogen: PA1-10019).

    Techniques: Staining

    Positive area-staining by antibody in intraperitoneally-treated GHK-Cu mice of both sexes for (A) TGF-β, (B) GFAP), (C) MCP-1, (D) p21, (E) Synaptophysin, (F) pSMAD-2, and (G) PSD-95. * P < 0.05, ** P < 0.01, **** P < 0.0001.

    Journal: bioRxiv

    Article Title: Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs

    doi: 10.64898/2026.04.09.717524

    Figure Lengend Snippet: Positive area-staining by antibody in intraperitoneally-treated GHK-Cu mice of both sexes for (A) TGF-β, (B) GFAP), (C) MCP-1, (D) p21, (E) Synaptophysin, (F) pSMAD-2, and (G) PSD-95. * P < 0.05, ** P < 0.01, **** P < 0.0001.

    Article Snippet: Following blocking, sections were incubated overnight at 4°C with primary antibodies against synaptophysin (1:250, Invitrogen MA5-16402), PSD95 (1:250, Abcam ab18258), phospho-SMAD2 (1:50, Invitrogen 44-244G), MCP-1 (1:800, Novus NBP1-07035), p21 (1:200, Abcam ab188224), TGF-β (1:50, Abcam ab215715), and GFAP (1:1500, Invitrogen: PA1-10019).

    Techniques: Staining

    METH enhances HIV-1 NL4-3 replication in HBVPs independently of Sigma-1R. A - B Impact of METH (25 µM) on HIV-1 replication as measured by p24 antigen release levels in HBVPs infected with HIV-1 NL4-3 ( A ) or JR-CSF ( B ). Data are means ± SEM ( n = 3). C - D Impact of METH (25 µM) on HIV-1 replication as measured by HIV-1 Gag mRNA expression levels in HBVPs infected with HIV-1 NL4-3 ( C ) or JR-CSF ( D ) ( n = 4–5). E Impact of pretreatment with S1RA (10 µM) for 6 h on NL4-3 HIV-1 replication in the presence and absence of METH ( n = 3–4). F Impact of HBVP pretreatment with the CXCR4 chemokine receptor antagonist AMD070 (5 µM) for 1 h on HIV-1 NL4-3 replication in the presence and absence of METH ( n = 4). G The heat map demonstrating the impact of HIV-1 NL4-3 infection and/or METH treatment for 72 h on gene expression profile of 42 ISGs in HBVPs ( n = 6). Genes with high expression levels are represented in shades of red, while those with low expression levels are shown in shades of green. Gene names are shown on the x axis. Red arrows indicate genes that were significantly differentially regulated in the HIV-1 NL4-3 + METH group compared to the control group, as determined by the RT² Profiler PCR Array ( p < 0.05). H - K RT-qPCR analysis of mRNA expression of CCL2 ( H ), MX2 ( I ), IFI30 ( J ), and PRKD2 ( K ) in HBVPs infected with HIV-1 NL4-3 and/or treated with METH ( n = 12). L Impact of blocking endogenous CCL2 with anti-human CCL2 neutralizing antibody on p24 release in HIV-1 NL4-3-infected HBVPs, with or without METH, at 72 h post-infection ( n = 6). M Impact of pretreatment with the CXCR4 chemokine receptor antagonist AMD070 (5 µM) for 1 h on CCL2 release in the presence and absence of METH at 72 h post-infection ( n = 6). Data are means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. Abbreviations as in Fig. ; CCL2 - C-C motif chemokine ligand 2

    Journal: Journal of Neuroinflammation

    Article Title: Sigma-1 receptor regulates HIV-1 and methamphetamine-induced endothelial/pericyte barrier impairment via strain-specific inflammatory responses and mitochondrial dysregulation

    doi: 10.1186/s12974-026-03750-1

    Figure Lengend Snippet: METH enhances HIV-1 NL4-3 replication in HBVPs independently of Sigma-1R. A - B Impact of METH (25 µM) on HIV-1 replication as measured by p24 antigen release levels in HBVPs infected with HIV-1 NL4-3 ( A ) or JR-CSF ( B ). Data are means ± SEM ( n = 3). C - D Impact of METH (25 µM) on HIV-1 replication as measured by HIV-1 Gag mRNA expression levels in HBVPs infected with HIV-1 NL4-3 ( C ) or JR-CSF ( D ) ( n = 4–5). E Impact of pretreatment with S1RA (10 µM) for 6 h on NL4-3 HIV-1 replication in the presence and absence of METH ( n = 3–4). F Impact of HBVP pretreatment with the CXCR4 chemokine receptor antagonist AMD070 (5 µM) for 1 h on HIV-1 NL4-3 replication in the presence and absence of METH ( n = 4). G The heat map demonstrating the impact of HIV-1 NL4-3 infection and/or METH treatment for 72 h on gene expression profile of 42 ISGs in HBVPs ( n = 6). Genes with high expression levels are represented in shades of red, while those with low expression levels are shown in shades of green. Gene names are shown on the x axis. Red arrows indicate genes that were significantly differentially regulated in the HIV-1 NL4-3 + METH group compared to the control group, as determined by the RT² Profiler PCR Array ( p < 0.05). H - K RT-qPCR analysis of mRNA expression of CCL2 ( H ), MX2 ( I ), IFI30 ( J ), and PRKD2 ( K ) in HBVPs infected with HIV-1 NL4-3 and/or treated with METH ( n = 12). L Impact of blocking endogenous CCL2 with anti-human CCL2 neutralizing antibody on p24 release in HIV-1 NL4-3-infected HBVPs, with or without METH, at 72 h post-infection ( n = 6). M Impact of pretreatment with the CXCR4 chemokine receptor antagonist AMD070 (5 µM) for 1 h on CCL2 release in the presence and absence of METH at 72 h post-infection ( n = 6). Data are means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. Abbreviations as in Fig. ; CCL2 - C-C motif chemokine ligand 2

    Article Snippet: To neutralize CCL2, cultures were incubated with an anti-human CCL2 neutralizing antibody (8 μg/mL; R&D Systems, Cat# AF-279-NA) or with normal goat IgG as a control (R&D Systems, Cat# AB-108-C).

    Techniques: Infection, Expressing, Gene Expression, Control, Quantitative RT-PCR, Blocking Assay

    Synergistic impact of METH and CXCR4-Tropic HIV-1 on pericyte-dependent endothelial barrier breakdown via CXCR4/CCL2-driven viral replication and Sigma-1R-mediated mitochondrial and inflammatory dysregulation. This proposed model depicts intersecting pathways through which CXCR4-tropic HIV-1 and METH synergistically compromise endothelial barrier integrity via viral replication, Sigma-1R-mediated mitochondrial dysfunction, and modulation of IL6-associated inflammatory response. Notably, METH-enhanced replication of CXCR4-tropic HIV-1 in pericytes appears to occur independently of the Sigma-1R signaling ( www.BioRender.com )

    Journal: Journal of Neuroinflammation

    Article Title: Sigma-1 receptor regulates HIV-1 and methamphetamine-induced endothelial/pericyte barrier impairment via strain-specific inflammatory responses and mitochondrial dysregulation

    doi: 10.1186/s12974-026-03750-1

    Figure Lengend Snippet: Synergistic impact of METH and CXCR4-Tropic HIV-1 on pericyte-dependent endothelial barrier breakdown via CXCR4/CCL2-driven viral replication and Sigma-1R-mediated mitochondrial and inflammatory dysregulation. This proposed model depicts intersecting pathways through which CXCR4-tropic HIV-1 and METH synergistically compromise endothelial barrier integrity via viral replication, Sigma-1R-mediated mitochondrial dysfunction, and modulation of IL6-associated inflammatory response. Notably, METH-enhanced replication of CXCR4-tropic HIV-1 in pericytes appears to occur independently of the Sigma-1R signaling ( www.BioRender.com )

    Article Snippet: To neutralize CCL2, cultures were incubated with an anti-human CCL2 neutralizing antibody (8 μg/mL; R&D Systems, Cat# AF-279-NA) or with normal goat IgG as a control (R&D Systems, Cat# AB-108-C).

    Techniques: